

## Supplemental Information

**SUPPLEMENTAL TABLE 5** Summary of GMTs of Vaccine-HPV Types 6, 11, 16, and 18 Through 10 Years for the EVG and Through 8 Years for the CVG After Dose 1 of the 4vHPV Vaccine Among the Per-Protocol Immunogenicity Population

	EVG				CVG			
	Age 9–12 y (N = 692)		Age 13–16 y (N = 487)		Age 11–15 y (N = 692)		Age 16–18 y (N = 487)	
	GMT, mMU/mL	Seropositivity, %	GMT, mMU/mL	Seropositivity, %	GMT, mMU/mL	Seropositivity, %	GMT, mMU/mL	Seropositivity, %
<b>HPV-6</b>								
Day 1	<8	0.0	<8	0.0	<8	0.0	<8	0.0
Mo 7	1055.8	99.8	762.5	99.7	793.3	99.5	676.7	100
Mo 96	76.4	89.5	62.9	86.0	99.6	90.0	98.0	99.5
Mo 102	96.3	92.0	81.1	90.5	—	—	—	—
Mo 108	106.7	94.0	94.9	91.5	—	—	—	—
Mo 114	97.1	91.3	77.1	89.0	—	—	—	—
Mo 120	91.6	91.4	73.9	87.5	—	—	—	—
Mo 126	91.4	90.1	76.9	86.8	—	—	—	—
<b>HPV-11</b>								
Day 1	<8	0.0	<8	0.0	<8	0.0	<8	0.0
Mo 7	1589.3	99.8	1074.8	99.7	1066.7	100	965.2	100
Mo 96	74.6	91.2	55.9	85.4	96.8	92.2	92.9	95.5
Mo 102	81.9	91.3	64.2	86.4	—	—	—	—
Mo 108	100.2	94.0	86.3	90.8	—	—	—	—
Mo 114	86.8	91.7	71.1	86.0	—	—	—	—
Mo 120	86.6	92.1	68.4	88.9	—	—	—	—
Mo 126	78.7	89.7	66.9	86.8	—	—	—	—
<b>HPV-16</b>								
Day 1	<12	0.0	<12	0.0	<12	0.0	<12	0.0
Mo 7	6487.2	99.7	4282.6	99.7	4582.7	100	3572.7	100
Mo 96	342.0	97.9	296.6	94.8	—	95.7	—	100
Mo 102	379.2	98.6	322.1	95.2	—	—	—	—
Mo 108	426.2	98.9	327.5	96.0	—	—	—	—
Mo 114	369.4	98.2	309.1	94.0	—	—	—	—
Mo 120	352.0	98.2	306.4	94.3	—	—	—	—
Mo 126	336.4	97.0	289.4	94.0	—	—	—	—
<b>HPV-18</b>								
Day 1	<8	0.0	<8	0.0	<8	0.0	<8	0.0
Mo 7	1556.6	99.8	943.3	99.7	871.9	99.5	714.7	100
Mo 96	46.8	89.5	33.4	86.0	41.6	90.0	32.9	95.5
Mo 102	47.3	92.0	32.6	90.5	—	—	—	—
Mo 108	47.6	94.0	35.0	91.5	—	—	—	—
Mo 114	44.7	91.3	30.7	89.0	—	—	—	—
Mo 120	45.7	91.4	30.0	87.5	—	—	—	—
Mo 126	41.0	90.1	28.9	86.8	—	—	—	—

GMTs are displayed in 2 age groups and in all subjects within the EVG (9–12 and 13–16 years old) and in 2 age groups and in all subjects in the CVG (11–15 and 16–18 years old). Data from all time points until month 96 have been published.<sup>4</sup> mMU, milli-Merck units; N, number of subjects in the indicated group who received at least 1 dose of the 4vHPV vaccine; —, not applicable.